Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lambda interferon inhibits hepatitis B and C virus replication.

Michael D Robek1, Bryan S Boyd, Francis V Chisari

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. michael.robek@yale.edu

Journal of Virology
|February 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Compensatory relationships determine the impact of TGF-β on the humoral immune response to hepatitis B surface antigen.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

The subset of M1-paired MHC class II conformers is critical for CD4+ T cell activation.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

High antigen burden drives CD8+ T cell dysfunction in a mouse model of chronic hepatitis B virus infection.

Journal of virology·2025
Same author

CD40 stimulation activates CD8+ T cells and controls HBV in CD4-depleted mice.

JHEP reports : innovation in hepatology·2024
Same author

Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.

JHEP reports : innovation in hepatology·2024
Same author

CD4<sup>+</sup> T cells reverse surface antigen persistence in a mouse model of HBV replication.

Microbiology spectrum·2023
Same journal

Something old, something new? Herpesvirus genome packaging examined in light of lessons from the tailed bacteriophages.

Journal of virology·2026
Same journal

Receptor profiling and growth assessment of influenza A virus in porcine mammary and non-mammary tissues and derived cells.

Journal of virology·2026
Same journal

Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.

Journal of virology·2026
Same journal

Structure and functional analyses of vaccinia virus J5 protein reveal distinct determinants for entry-fusion complex assembly and activation.

Journal of virology·2026
Same journal

Coronavirus membrane protein with a fluorescent protein tag enables particle tracking for the study of virus assembly and egress in live cells.

Journal of virology·2026
Same journal

Disruption of the S1/S2 multibasic cleavage site attenuates infectious bronchitis virus, while S2' partially restores viral virulence and expands tissue tropism.

Journal of virology·2026
See all related articles

Lambda interferon (IFN-lambda) shows promise for treating chronic hepatitis B and C. This novel interferon effectively inhibits both hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in cell models.

Area of Science:

  • Virology
  • Immunology
  • Hepatology

Background:

  • Interferon-lambda (IFN-lambda) activates antiviral responses via a unique receptor.
  • Its therapeutic potential against chronic viral hepatitis remains largely unexplored.

Purpose of the Study:

  • To investigate the efficacy of IFN-lambda in inhibiting hepatitis B virus (HBV) and hepatitis C virus (HCV) replication.

Main Methods:

  • Murine hepatocytes were used to assess HBV replication inhibition.
  • Human hepatocyte Huh7 cells were employed to evaluate HCV replicon replication.

Main Results:

  • IFN-lambda demonstrated comparable kinetics and efficiency to IFN-alpha/beta in inhibiting HBV replication.
  • IFN-lambda effectively blocked replication of both subgenomic and full-length HCV replicons.

Related Experiment Videos

Conclusions:

  • IFN-lambda exhibits potent antiviral activity against HBV and HCV in vitro.
  • These findings suggest IFN-lambda as a potential therapeutic agent for chronic HBV and HCV infections.